Concepedia

David B. Wainscott

DB

Statistics

Publications

36

Citations

3.1K

H-Index

27

Active since

1992

Affiliations

Eli Lilly (United States)(Current)

Purdue University West Lafayette

Indiana University – Purdue University Indianapolis

CNS Research (United States)

ConfometRx (United States)

David B. Wainscott is an author at Eli Lilly (United States) specializing in pharmacology, medicine, and medicinal chemistry.

ORCID

Publications per year

1992–2024

36

Publications

36

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist

Francis S. Willard, Jonathan D. Douros, M Gabe et al. · JCI Insight · 2020 · 487 citations · Full text

, , +17

LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept

Tamer Coşkun, Shweta Urva, William C. Roell et al. · Cell Metabolism · 2022 · 276 citations · Full text

, , +17

Preclinical pharmacological profile of the selective 5-HT <sub>1F</sub> receptor agonist lasmiditan

David L. Nelson, Lee A. Phebus, Kirk W. Johnson et al. · Cephalalgia · 2010 · 212 citations · Full text

, , +15

Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist

Takahiro Kawai, Bingfa Sun, Hitoshi Yoshino et al. · Proceedings of the National Academy of Sciences · 2020 · 192 citations · Full text

, , +17

Molecular cloning, functional expression, and pharmacological characterization of a novel serotonin receptor (5-hydroxytryptamine2F) from rat stomach fundus.

Jonathan D. Kursar, David L. Nelson, David B. Wainscott et al. · Molecular Pharmacology · 1992 · 183 citations

, , +16

1–5 of 36